Thomas Steyer Farallon Capital Management
Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
APC
Anadarko Petroleum
APC
|
+$702M |
| 2 |
CELG
Celgene Corp
CELG
|
+$666M |
| 3 |
WCG
Wellcare Health Plans, Inc.
WCG
|
+$459M |
| 4 |
RHT
Red Hat Inc
RHT
|
+$333M |
| 5 |
AGN
Allergan plc
AGN
|
+$138M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TransUnion
TRU
|
+$181M |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$173M |
| 3 |
Meta Platforms (Facebook)
META
|
+$169M |
| 4 |
Booking.com
BKNG
|
+$157M |
| 5 |
GG
Goldcorp Inc
GG
|
+$148M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 38.49% |
| 2 | Technology | 17.66% |
| 3 | Communication Services | 14.59% |
| 4 | Industrials | 6.69% |
| 5 | Energy | 5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Microsoft
MSFT
$3.59T
| $168M | 1.1% |
1,257,503
-372,898
| -23% | -$47.3M |
|
|
AGN
27
DELISTED
Allergan plc
AGN
| $167M | 1.09% |
+1,000,000
| New | +$138M |
|
28
Cigna
CI
$73.3B
| $165M | 1.08% |
1,050,000
+105,000
| +11% | +$16.5M |
|
|
29
Alphabet (Google) Class C
GOOG
$4.18T
| $154M | 1% |
2,844,460
-3,002,100
| -51% | -$173M |
|
30
Iovance Biotherapeutics
IOVA
$3.76B
| $140M | 0.91% |
5,725,000
| – | – |
|
|
31
TransUnion
TRU
$16.2B
| $123M | 0.8% |
1,672,343
-2,645,503
| -61% | -$181M |
|
32
Sea Limited
SE
$72B
| $112M | 0.73% |
3,375,000
-3,545,000
| -51% | -$96.1M |
|
|
MRTX
33
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $102M | 0.67% |
995,000
-205,000
| -17% | -$16M |
|
|
MYOK
34
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $100M | 0.65% |
2,000,000
+49,722
| +3% | +$2.42M |
|
|
XLRN
35
DELISTED
Acceleron Pharma
XLRN
| $97.6M | 0.63% |
2,375,000
| – | – |
|
36
Liberty Global Class C
LBTYK
$3.55B
| $97.5M | 0.63% |
3,675,974
-632,132
| -15% | -$16.2M |
|
|
ZGNX
37
DELISTED
Zogenix, Inc.
ZGNX
| $95.6M | 0.62% |
2,000,000
-50,500
| -2% | -$2.03M |
|
|
ZAYO
38
DELISTED
Zayo Group Holdings, Inc.
ZAYO
| $92.8M | 0.6% |
+2,820,000
| New | +$90M |
|
|
SAGE
39
DELISTED
Sage Therapeutics
SAGE
| $91.5M | 0.6% |
500,000
-100,000
| -17% | -$17.1M |
|
40
Alibaba
BABA
$286B
| $84.7M | 0.55% |
500,000
+85,000
| +20% | +$14.7M |
|
|
AMRN
41
Amarin Corp
AMRN
$298M
| $82.4M | 0.54% |
212,500
+50,000
| +31% | +$18.3M |
|
42
Enanta Pharmaceuticals
ENTA
$392M
| $81M | 0.53% |
960,000
+20,000
| +2% | +$1.8M |
|
43
Alnylam Pharmaceuticals
ALNY
$31.6B
| $79.8M | 0.52% |
1,100,000
+600,000
| +120% | +$46M |
|
|
ONCE
44
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $78.8M | 0.51% |
770,000
-50,000
| -6% | -$5.4M |
|
|
GWR
45
DELISTED
Genesee & Wyoming Inc.
GWR
| $77.5M | 0.5% |
+775,000
| New | +$70.7M |
|
|
KYNB
46
Kyntra Bio
KYNB
$30.4M
| $76.8M | 0.5% |
68,000
+31,377
| +86% | +$34.3M |
|
47
Sarepta Therapeutics
SRPT
$1.98B
| $76M | 0.49% |
500,000
-150,000
| -23% | -$18.2M |
|
48
NovoCure
NVCR
$1.99B
| $75.9M | 0.49% |
1,200,000
+150,000
| +14% | +$7.6M |
|
|
RETA
49
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $75.5M | 0.49% |
800,000
+50,000
| +7% | +$4.32M |
|
|
S
50
DELISTED
Sprint Corporation
S
| $70.1M | 0.46% |
10,675,000
+9,085,000
| +571% | +$57.4M |
|
Similar funds
Thomas Steyer's Q2 2019 Portfolio in Review
As of Q2 2019, Thomas Steyer held 115 positions worth $15.4B, up 16% from $13.3B the previous quarter. Its ten largest holdings account for 55% of the portfolio.
Thomas Steyer deployed $1.36B of net new capital in Q2 2019, opening 20 new positions and adding to 35 existing holdings. Its largest new stake was Anadarko Petroleum: 10,465,000 shares worth $738M.
By sector, the portfolio is most concentrated in Healthcare at 38% of assets, up from 30% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was TransUnion, an estimated $181M trimmed.
- Thomas Steyer's largest Q2 2019 buy was Anadarko Petroleum: 10,465,000 shares worth $738M.
- Thomas Steyer added most to Celgene Corp in Q2 2019, an estimated $666M increase.
- Thomas Steyer's biggest Q2 2019 reduction was TransUnion, cutting an estimated $181M.
- Thomas Steyer fully exited Goldcorp Inc in Q2 2019, selling an estimated $148M.
- Thomas Steyer's ten largest holdings make up 55% of its $15.4B portfolio in Q2 2019.
- Thomas Steyer opened 20 new positions and closed 11 in Q2 2019.
- Thomas Steyer's portfolio value rose 16% quarter-over-quarter to $15.4B.
Based on Farallon Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.